Alzheimer’s disease (AD) drug development remains the most high-risk, high-investment domain in biopharma. The so-called Alzheimer’s graveyard reflects decades of scientific promise undermined by regulatory, operational, and strategic misalignment. However, the landscape is evolving. The emergence of amyloid- and tau-targeting therapies has demonstrated that regulatory success is achievable when supported by disciplined development strategy and risk architecture.